BeyondSpring (NASDAQ:BYSI – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect BeyondSpring to announce earnings of ($0.54) per share and revenue of $8.7670 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.
BeyondSpring (NASDAQ:BYSI – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49.
BeyondSpring Price Performance
Shares of NASDAQ:BYSI opened at $0.99 on Wednesday. The company has a market capitalization of $40.71 million, a PE ratio of -7.07 and a beta of 0.48. The business has a fifty day moving average price of $1.51 and a two-hundred day moving average price of $1.54. BeyondSpring has a 1 year low of $0.99 and a 1 year high of $2.44.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on BYSI
Institutional Inflows and Outflows
A hedge fund recently bought a new position in BeyondSpring stock. State Street Corp bought a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned 0.57% of BeyondSpring as of its most recent SEC filing. Institutional investors own 40.29% of the company’s stock.
BeyondSpring Company Profile
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
Further Reading
- Five stocks we like better than BeyondSpring
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
